About Micromet
Micromet is a Healthcare company based in Munchen (Germany) founded in 1993. It develops antibodies using proprietary BiTe platform technology. Micromet has raised $10.5 million across 3 funding rounds from investors including BMBF. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Micromet GmbH.
Company details
The company was founded in 1993 in Munich, Germany, and operated in the biotechnology sector. Novel antibodies were developed for treating cancer, inflammation, and autoimmune diseases using the proprietary BiTE platform, which activates patient T cells to target diseased cells. The lead product, blinatumomab, was advanced for cancer therapy. Operations ceased following acquisition by Amgen in January 2012.
- Headquarters Munchen, Germany
- SectorsHealthcare
- Website ww16.micromet.de/?sub1=20250730-2000-2462-8ce1-016a81c1955c
- Legal Name Micromet Gmbh
- Annual Revenue$22.39 M (USD)-43as on Dec 31, 2011
- Net Profit$57.8 M (USD)224as on Dec 31, 2011
- Total Equity Funding$10.5M (USD)
in 3 rounds
- Latest Funding Round$75M (USD), Post-IPO
Aug 2009
- Investors
Funding Insights of Micromet
Micromet has successfully raised a total of $10.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $75 million completed in August 2009. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.5M
- Total Rounds 3
- Last Round Post-IPO — $75M
- First Round $1.4M
(Jul 1998)
- Investors Count 1
All 3 funding rounds of Micromet with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2009 | $75M | Post-IPO | – | – | – |
| Apr 2000 | $10.5M | Series A | – | – | – |
| Jul 1998 | $1.4M | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Micromet
Micromet has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include BMBF.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Education and research policies are overseen by the ministry. | 1955 | bmbf.de | Berlin, Germany |
Investor details for Micromet
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Micromet
3 dated milestones of Micromet across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Micromet is founded.
- Funding First funding round of $1.4M.
- Funding Latest funding round, Post-IPO, of $75.0M.
Web traffic of Micromet
Websites that share an audience with Micromet (micromet.de).
Websites whose visitors overlap most with Micromet. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
biotica.co.uk | biotica.co.uk | 100% | – | ||
crusadelabs.co.uk | crusadelabs.co.uk | 100% | – | ||
| acimmune.com | 100% | 11.3K | #1,671,085 | View details | |
| allos.com | 100% | View details | |||
cancervaccines.com | cancervaccines.com | 100% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 19 similar websites and full traffic analytics for Micromet
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 19 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Micromet
Complete news archive for Micromet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Micromet
Micromet was founded in 1993 and raised its 1st funding round 5 years after it was founded.
Micromet is headquartered in Munchen, Germany. It is registered at Munchen, Bayern, Germany.
Micromet is a funded company, having raised a total of $10.5M across 3 funding rounds to date. The company's 1st funding round was a Grant of $1.4M, raised on Jul 1998.
Annual revenue of Micromet is $22.39M as on Dec 31, 2011.
The company was founded in 1993 in Munich, Germany, and operated in the biotechnology sector. Novel antibodies were developed for treating cancer, inflammation, and autoimmune diseases using the proprietary BiTE platform, which activates patient T cells to target diseased cells. The lead product, blinatumomab, was advanced for cancer therapy. Operations ceased following acquisition by Amgen in January 2012.
Micromet has 1 investor. Key investors include BMBF.
Micromet operates through Micromet Gmbh.